NCT05516680

Brief Summary

Introduction: Post-stroke depression (PSD) is the most common mental complication after stroke and has a serious impact on functional outcomes and quality of life. Antidepressants are the first-line treatment for PSD, but many reported side effects remain. Clinical research and practice guidelines have shown that electro-acupuncture and rTMS have a positive effect on PSD. This trial aims to study the efficacy and safety of electro-acupuncture and a modern MRI-navigated rTMS for PSD and to explore its fMRI-based central mechanism on depression. It is hypothesized that electro-acupuncture and MRI-navigated rTMS treatment improves depressive symptoms, neuro-patho-physiological behaviors, quality of life and central response in PSD. Methods: In this randomized, controlled, assessors-blinded trial, sixty-four patients with PSD will be randomly allocated into the experiment group (n=32) or control group(n=32) . The experiment group will receive electro-acupuncture and MRI-navigated rTMS, and the control group will receive MRI-navigated rTMS treatment, in 12-20 sessions over 4 weeks. In addition, ten healthy people for fMRI scanning will be recruited as a healthy control group without any intervention. The primary outcome is the change from baseline in the Hamilton Depression Scale-24 items (HAMD-24) scores at week 4. The primary analysis of central mechanism mainly involves cortical morphology, local spontaneous brain activity, and default mode network (DMN) functional connectivity based on fMRI at 0-wk and 4-wk. Secondary outcomes include the neuro-patho-physiological and quality of life changes in cortical excitability with motor evoked potential test(MEP), National Institutes of Health Stroke Scale(NIHSS), EuroQol Five Dimensions Questionnaire(EQ-5D) Scale, Modified Barthel Index(MBI) Scale and Short Form-Health Scale of Traditional Chinese Medicine(SF-HSTCM). Additional indicators include the Acceptability Questionnaire and Health Economics Evaluation (cost-effectiveness analysis) to assess acceptability and economic practicality of the treatment in study. Outcomes are assessed at baseline and post intervention. Discussion: Electro-acupuncture and MRI-navigated rTMS therapy could become an alternative treatment for PSD, and it is expected that this trial will provide reliable clinical evidence and potential effect mechanism for the future use of electro-acupuncture and MRI-navigated rTMS for PSD.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
64

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 15, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

August 25, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

October 22, 2022

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2025

Completed
Last Updated

March 23, 2023

Status Verified

August 1, 2022

Enrollment Period

2.7 years

First QC Date

August 15, 2022

Last Update Submit

March 22, 2023

Conditions

Outcome Measures

Primary Outcomes (3)

  • Hamilton Depression Scale-24 items scores

    Reduction rate

    change from baseline to week 4

  • fMRI scan

    Cortical morphology, local spontaneous brain activity, and default mode network (DMN) functional connectivity

    0 week

  • fMRI scan

    Cortical morphology, local spontaneous brain activity, and default mode network (DMN) functional connectivity

    4 weeks

Secondary Outcomes (10)

  • motor evoked potential test

    0 week

  • motor evoked potential test

    4 weeks

  • National Institutes of Health Stroke Scale

    0 week

  • National Institutes of Health Stroke Scale

    4 weeks

  • EuroQol Five Dimensions Questionnaire Scale

    0 week

  • +5 more secondary outcomes

Other Outcomes (2)

  • Acceptability Questionnaire

    4 weeks

  • Health Economics Evaluation

    4 weeks

Study Arms (2)

Experiment group

EXPERIMENTAL

electro-acupuncture and MRI-navigated rTMS

Device: electro-acupunctureDevice: MRI-navigated rTMS

Control group

ACTIVE COMPARATOR

MRI-navigated rTMS

Device: MRI-navigated rTMS

Interventions

Acupoints consist of Neiguan (PC6, bilateral), Shuigou (GV26), Sanyinjiao (SP6, affected side), Yintang (EX-HN3), Shangxing (GV23), Baihui (GV20), and Sishencong (EX-HN1). Disposable stainless-steel needles (0.25mm× 40 mm)will be used. After skin disinfection, the acupuncturists will twist and thrust the needle handles to achieve the sensation of achiness, heaviness, and numbness (known as de qi) at all acupoints. Following needle manipulations, electroacupuncture instruments(SDZ-V) will be used to attached the needle handles at EX-HN3, GV23, GV20 and EX-HN1 with a dilatational wave of 5 \~ 10 Hz and a current intensity of 1 \~ 3 mA depending on the patient's tolerance. The needles will be removed after 30 minutes except for GV26 without needle retention. Participants will receive 12-20 electroacupuncture sessions over four weeks at a frequency of 3-5 times per week.

Experiment group

MRI:All MRI scans were taken to acquire high-resolution T1-weighted anatomical images on the 3T MRI Scanner. Electromyography(EMG):Surface EMG was used to record MEPs from the abductor pollicis brevis for determining RMT of the non-lesioned motor cortex.A single TMS pulse was delivered to the location to identify the RMT,defined as the minimum intensity capable of evoking at least 5 MEPs of \>50 μV in 10 consecutive trials.MRI-navigated rTMS:Using BrainSight system,left DLPFC targeting was individualized by reconstructing MRI data into a 3-dimensional brain image for neuro-navigation. Left DLPFC localization was central middle frontal gyrus,between superior frontal sulcus and middle frontal sulcus based on T1-weighted anatomical images.Focal rTMS was administered using a Magstim Rapid 2 connected to Y125-round coil that was identical.rTMS was applied at 110% RMT to the left DLPFC.At each session,3000 pulses were applied at 10 Hz with a total of 12-20 rTMS sessions over a 4-week period.

Control groupExperiment group

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Meet the TCM and Western medicine diagnostic criteria for first onset stroke within 6 months;
  • Aged 40-75 years;
  • Right-handed;
  • Single infarct in basal ganglia (volume:3-5cm);
  • Motor evoked potential (MEP) could be recorded by bilateral primary motor cortex (M1) stimulating.
  • National Institutes of Health Stroke Scale (NIHSS) score \<6;
  • Hamilton Depression Scale-24 items (HAMD-24) score \> 8;
  • Clear consciousness, no hearing and visual impairment, and cooperative physical examination (Glasgow Coma Scale (GCS) score \> 8);
  • Complete the screening, and sign the informed consent form voluntarily.
  • Healthy subjects, aged 40-75 years;
  • Right-handed;
  • HAMD-24 score \< 8;
  • Sign the informed consent voluntarily.

You may not qualify if:

  • Have received other antidepressant therapy or involved in other clinical trials in 2 weeks;
  • Infarct was located in the left DLPFC;
  • With positive psychiatric history and major trauma exposure history, such as depression, epilepsy, etc. in the past;
  • With other serious concomitant diseases (aphasia, severe edema, venous thrombosis, arteriosclerosis occlusion, diabetic vascular disease, peripheral neuropathy, spinal lesions, brain trauma, intracranial infection, brain tumors, etc.), and secondary diseases (heart, liver, renal failure, etc.);
  • Infection around acupoints and/or intolerance of acupuncture manipulation;
  • With MRI or rTMS contraindications (claustrophobia, metal implants, cochlear implants, impulsator, etc.).
  • Have involved in other clinical trials in 2 weeks;
  • With positive psychiatric history and major trauma exposure history, including depression, epilepsy, etc. in the past;
  • With MRI or rTMS contraindications (claustrophobia, metal implants, cochlear implants, impulsator, etc.).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Drum Tower Hospital, Medical School of Nanjing University

Nanjing, Jiangsu, 210008, China

RECRUITING

Related Publications (1)

  • Lu H, Wang Y, Shen D, Ruan J, Lu J, Wang L, Song Y, Fan J, Li D, Shi L, Xia M, Xu T. Effects and central mechanism of electroacupuncture and MRI-navigated rTMS for PSD: study protocol for an fMRI-based single-center, randomized, controlled, open-label trial. Front Psychiatry. 2024 Jan 4;14:1226777. doi: 10.3389/fpsyt.2023.1226777. eCollection 2023.

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 15, 2022

First Posted

August 25, 2022

Study Start

October 22, 2022

Primary Completion

June 30, 2025

Study Completion

August 1, 2025

Last Updated

March 23, 2023

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will share

IPD sharing will be made during the 6 months after the end of study, and the original data can be obtained from the PI if necessary.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
During the 6 months after the end of study.

Locations